Cargando…

Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases

Detalles Bibliográficos
Autores principales:	Lam, Marnix G. E. H., Zonnenberg, Bernard A.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440968/ http://dx.doi.org/10.1007/s00259-008-0782-5

Ejemplares similares

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study
por: Lam, Marnix G. E. H., et al.
Publicado: (2009)

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2007)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Prostate-specific antigen for prediction of skeletal metastases on bone scintigraphy in prostate cancer
por: Hammond, Emmanuel Nii Boye, et al.
Publicado: (2021)

Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
por: Cox, R A, et al.
Publicado: (2008)

Very high-risk prostate cancer: multimodality treatment will be the new frontier
por: Campobasso, Davide, et al.
Publicado: (2017)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Positron emission tomography/computed tomography is superior to bone scan in the diagnosis of bone metastases of malignant prostate tumors
por: Sun, Yue, et al.
Publicado: (2022)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Breast cancer bone metastases: an orthopedic emergency
por: Piccioli, Andrea
Publicado: (2013)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Multimodal treatments of “gallstone cholangiopancreatitis”
por: Vanella, Serafino, et al.
Publicado: (2022)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Multimodal treatment for a Brazilian case of hikikomori
por: Roza, Thiago H., et al.
Publicado: (2020)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Mediastinal cryptococcosis masquerading as therapy-refractory lymphoma
por: Wong, Matthew, et al.
Publicado: (2010)

Squamous cell carcinoma of the paranasal sinuses: cutaneous metastases with bone involvement
por: Ribeiro, Bruno Niemeyer de Freitas, et al.
Publicado: (2018)

Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
por: Alonso‐Gordoa, Teresa
Publicado: (2022)

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
por: Berruti, A, et al.
Publicado: (2005)

Successful treatment of a refractory pyoderma gangrenosum with risankizumab
por: Burgdorf, Birte, et al.
Publicado: (2020)

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases
por: Bryden, A A G, et al.
Publicado: (2002)

Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?
por: Knipper, Sophie, et al.
Publicado: (2021)

Late and acute reaction to iohexol, refractory to treatment
por: Choudhury, Minati, et al.
Publicado: (2011)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

The coronary sinus reducer for the treatment of refractory angina
por: Paz, Y., et al.
Publicado: (2016)

RE: Paper by Fornai C, Tester I, Parlett K, Basili C, Costa HN. J Oral Rehabil. 2022 Apr 4. [Online ahead of print]
por: Zonnenberg, Adriaan J. J., et al.
Publicado: (2022)

Cannonball Pulmonary Metastases in Gallbladder Cancer
por: Agarwal, Rakesh, et al.
Publicado: (2017)

Pelvic Bone Fractures Mimicking Bone Metastases in a Patient with Hepatitis B Virus-Associated Liver Cirrhosis and Hepatocellular Carcinoma
por: Lee, Dong Hyeon, et al.
Publicado: (2012)

A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors
por: Lo Bianco, Giuliano, et al.
Publicado: (2022)

Observations on Prostatic Cancer with Metastases in Bone
por: Charteris, Alexander A.
Publicado: (1927)

Update in palliative management of hormone refractory cancer of prostate
por: Singh, Pratipal, et al.
Publicado: (2007)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Multimodal sequential treatment for occluded TIPS: Case report and review of literature
por: De Matthaeis, Nicoletta, et al.
Publicado: (2020)

Successful multimodal treatment of stage IV lymphoepithelioma-like thymic carcinoma
por: Zielińska, Dominika, et al.
Publicado: (2022)

Synovial sarcoma with isolated bone metastases, demonstrated by (99m)Tc-MDP bone scintigraphy and (18)F-FDG PET/CT
por: Senthil, Raja, et al.
Publicado: (2012)

Osteosarcoma metastases in penis
por: Aparna, C., et al.
Publicado: (2013)

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy
por: Wenter, Vera, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e70jdlndv4k0vv678muu1ie77r